Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 12,238 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Ulcerative Colitis
Interventions: BT051 200 mg, BT051 800 mg, BT051 3200 mg, Matching Placebo; Drug
Lead sponsor: Adiso Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Rialto, California • Kissimmee, Florida

Conditions: Acne Vulgaris
Interventions: Adapalene Gel 0.3%, Differin 0.3% Topical Gel, Adapalene Gel 0.3% Vehicle Placebo; Drug
Lead sponsor: Aleor Dermaceuticals Limited; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 9
States / cities: Sherman Oaks, California • Brandon, Florida • Miami, Florida + 4 more

Conditions: Biliary Atresia
Interventions: Filgrastim; Drug
Lead sponsor: Holterman, Ai-Xuan, M.D.; Individual
Eligibility: 14 Days to 180 Days
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hemophilia A
Interventions: BAY94-9027; Biological
Lead sponsor: Bayer; Industry
Eligibility: Up to 12 Years · Male only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 7
States / cities: Sacramento, California • Pensacola, Florida • Cincinnati, Ohio + 4 more

Conditions: Paroxysmal Supraventricular Tachycardia (PSVT)
Interventions: Etripamil, Placebo; Drug
Lead sponsor: Milestone Pharmaceuticals Inc.; Other
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 26
States / cities: Phoenix, Arizona • Sacramento, California • Littleton, Colorado + 19 more

Conditions: Multiple Myeloma
Interventions: Carfilzomib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: IgA Nephropathy (IgAN)
Interventions: Avacopan, Prednisone, Methylprednisolone (drug), Prednisolone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT; Biological · Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: Up to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hypertension
Interventions: Nebivolol; Drug
Lead sponsor: Mylan Bertek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Cystic Fibrosis, Pancreatic Cystic Fibrosis
Interventions: Behavioral and Nutrition Treatment, Education and Attention Control; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 2 Years to 6 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 5
States / cities: Tucson, Arizona • Ann Arbor, Michigan • Cincinnati, Ohio + 2 more

Conditions: Duchenne Muscular Dystrophy
Interventions: HT-100; Drug
Lead sponsor: Processa Pharmaceuticals; Industry
Eligibility: 6 Years to 20 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Sacramento, California • Baltimore, Maryland • St Louis, Missouri + 2 more

Conditions: Hypertension
Interventions: Self-Measured Blood Pressure Monitoring, Physician appointment and transportation scheduling; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Acne
Interventions: IDP 121 Lotion, IDP-121 Vehicle Lotion; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 9 Years and older
Enrollment: 820 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 34
States / cities: Glendale, Arizona • Rogers, Arkansas • Anaheim, California + 27 more

Conditions: Dermatitis, Atopic
Interventions: LY3471851, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 20
States / cities: North Little Rock, Arkansas • Encinitas, California • Fremont, California + 17 more

Conditions: Neoplasms
Interventions: Cisplatin, Gemcitabine, Anetumab ravtansine (BAY94-9343); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • Stanford, California + 10 more

Conditions: Herniated Disc, Radiculopathy, Spondylolysis
Interventions: Fixed hole C-Tek™ Plate, Slotted hole C-Tek™ Plate; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 10 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 5
States / cities: Denver, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 2 more

Conditions: Heart Failure, Multiple Myeloma
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Nashville, Tennessee

Conditions: Osteoarthritis
Interventions: Customized patient instruments, Traditional Metal Instruments; Device
Lead sponsor: Medacta USA; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 5
States / cities: Marrero, Louisiana • Billings, Montana • Meadville, Pennsylvania + 2 more

Conditions: Concussion
Interventions: Transcranial direct current stimulation; Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 30 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: ATN-224 + bortezomib; Drug
Lead sponsor: Attenuon; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 10
States / cities: Fresno, California • West Hollywood, California • Fort Myers, Florida + 7 more

Conditions: DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly, Complete DiGeorge Syndrome, Complete Atypical DiGeorge Syndrome
Interventions: Cultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw, Rabbit anti-thymocyte globulin, Cyclosporine, Tacrolimus, Methylprednisolone or Prednisolone, Daclizumab, Mycophenolate mofetil; Biological · Other · Procedure + 1 more
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: Not listed
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Multiple Myeloma
Interventions: CC-92480, Tazemetostat, BMS-986158, Trametinib, Dexamethasone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 2 more

Conditions: Neuropathic Pain, Mechanical Hypersensitivity
Interventions: AZD2066, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 38
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 35 more

Search by objective public record fields.

An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia

Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm

Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma

Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients

Behavioral & Nutritional Treatment to Help CF Preschoolers Grow

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy

Reach Out 2: Emergency Department-Initiated Hypertension Mobile Health Intervention Connecting Multiple Health Systems

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

A Study of LY3471851 in Participants With Eczema

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

Slotted Hole Versus Fixed Hole C-Tek

Cystic Fibrosis Foundation (CFF) Biomarkers of Exacerbation

Prospective Observation of Cardiac Safety With Proteasome Inhibition

Single-use Efficiency Instruments With Patient Specific Technique (MyKnee®) Versus Traditional Metal Instruments With Conventional Surgical Technique

Cortical Plasticity Assessment in Athletes With a History of Concussion

A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma

Phase I/II Thymus Transplantation With Immunosuppression #950

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

AZD2066 Neuropathic Pain - Mechanical Hypersensitivity